Brief: Ascletis Pharma Inc Says Third-Party Petition Filed Against Company's U.S. Patent
30/06/2025 02:46
June 30 (Reuters) - Ascletis Pharma Inc 1672.HK: THIRD-PARTY PETITION FILED AGAINST COMPANY'S U.S. PATENT BECOME AWARE OF PETITION FOR POST GRANT REVIEW FILED WITH UNITED STATES PATENT AND TRADEMARK OFFICE BY CONJUPRO BIOTHERAPEUTICS PETITION CHALLENGED VALIDITY OF CLAIMS OF GRANTED U.S. PATENT NO. 12,234,236 OWNED BY ASCLETIS PHARMA (CHINA) CO PETITION REMAINS UNDER REVIEW BY USPTO AS AT JUNE 30 Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026